fenfluramine hydrochloride · Ucb Inc · NDA 212102

Fintepla

Earliest generic entry, as listed
29 Dec 2038

Blocked by patent: US 10452815.

Listed patents · 30 unexpired

PatentClaimsExpires
US 10452815—29 Dec 2038
US 10603290—2 Feb 2038
US 11040018—2 Feb 2038
US 11406606—2 Feb 2038
US 11759440—2 Feb 2038
US 11786487—2 Feb 2038
US 10603290use U-33472 Aug 2037
US 10603290use U-28612 Aug 2037
US 11040018use U-28612 Aug 2037
US 11040018use U-33472 Aug 2037
US 11406606use U-34062 Aug 2037
US 11406606use U-34072 Aug 2037
US 11759440use U-36942 Aug 2037
US 11786487use U-37332 Aug 2037
US 10947183—20 Jun 2037
US 10947183substance, product20 Dec 2036
US 10478441—3 Nov 2033
US 10478442—3 Nov 2033
US 12097206—3 Nov 2033
US 9549909—3 Nov 2033
US 9603814—3 Nov 2033
US 9603815—3 Nov 2033
US 9610260—3 Nov 2033
US 10478441use U-28603 May 2033
US 10478442use U-28603 May 2033
US 12097206use U-40133 May 2033
US 9549909use U-28583 May 2033
US 9603814use U-28583 May 2033
US 9603815use U-28583 May 2033
US 9610260use U-28583 May 2033

Exclusivities · 4 unexpired

PEDpediatric (6 months added)25 Sep 2029
ODE-393orphan drug (7 years)25 Mar 2029
PEDpediatric (6 months added)25 Dec 2027
ODE-312orphan drug (7 years)25 Jun 2027

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
212102 · 001 · RLDsolution, oralEQ 2.2MG BASE/ML29 Dec 2038
Expired or delisted (1)
  • US 10452815 · use U-2859 · 29 Jun 2038 · delisted